Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Inclusion Criteria: * Patients who enable to have standard operation * Patients who refuse standard preoperative chemotherapy and are diagnosed with following cancers; gastric adenocarcinoma, esophageal squamous cell carcinoma, non-small-cell lung carcinoma, renal cell carcinoma or oral squamous cell carcinoma * Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Patients with no serious disorder of major organs (born marrow, heart, lung, liver and kidney) * Patients with written informed consent * Patients who have measurable target lesion * Patients who are enable to undergo biopsy for sampling tumor tissue Exclusion Criteria: * Known or previous autoimmune disease * Known or suspected interstitial lung disease (ILD) * Patients with history of serious anaphylaxis induced by antibody preparation * Uncontrollable hypertension * Uncontrollable endocrine disease * Patients who have active inflammatory bowel disease or other serious GI chronic conditions associated with diarrhea * Uncontrollable diabetes * Prior therapy with sustained anticancer agents, radiotherapy or surgery for primary disease * Pregnant or lactating females, female and male patients who cannot agree to practice the adequate birth control after the consent during the study * Known or suspected infection or inflammatory disease * Prior therapy with hematopoietic stem cell transplantation * Known or suspected central nervous system (CNS) involvement